Login to Your Account

Single Asset Sends Ceptaris into Actelion's Arms

By Marie Powers
Staff Writer

Wednesday, July 31, 2013
Ceptaris Therapeutics Inc. found a home for its single asset, Valchlor (mechlorethamine gel), with Actelion U.S. Holdings Co., a subsidiary of Swiss drugmaker Actelion Ltd. But there's a catch: The $250 million deal is contingent upon FDA approval of the product.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription